Solasia Pharma K.K. signs License and Supply Agreement with Kyowa Hakko Kirin to market SP-01

Solasia Pharma K.K. (http://www.solasia.co.jp), a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today the signing of a License and Supply Agreement with Kyowa Hakko Kirin that provides Kyowa Hakko Kirin with an exclusive right to market and sell SP-01 (extended release transdermal granisetron patch; brand name: Sancuso®) in Taiwan, Hong Kong, Singapore and Malaysia.

“We are very excited to build upon our strong relationship with Kyowa Hakko Kirin, and look forward to seeing Sancuso launched in these Asian territories in the near future”

Under the terms of the agreement, Solasia will receive upfront, regulatory and sales milestones. Kyowa Hakko Kirin will be responsible for all commercialization activities in Taiwan, Hong Kong, Singapore and Malaysia. Solasia will supply product to Kyowa Hakko Kirin in these territories.

Sancuso is the first and only commercialized extended release granisetron transdermal product. In May 2008, Solasia acquired the exclusive right to Sancuso from ProStrakan Group plc. (www.prostrakan.com) for Japan, China, and other territories in Asia. Solasia retains full rights in Japan and China where it is currently conducting Sancuso clinical development activities. Sancuso was approved in the United States in September 2008 for the prevention of chemotherapy-induced nausea and vomiting.

“We are very excited to build upon our strong relationship with Kyowa Hakko Kirin, and look forward to seeing Sancuso launched in these Asian territories in the near future,” stated Solasia President Steve Engen.

Source:

Solasia Pharma K.K.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Experimental treatment for metastatic pancreatic cancer shows promise in phase 2 clinical trial